Can a jaw joint cartilage injection replace surgery?

For many people living with jaw pain, clicking, or restricted mouth opening, the question is not simply what is wrong — it is whether anything can be done without surgery. TMJ cartilage damage is a significant driver of all three symptoms, and traditional surgical routes carry a real recovery burden: arthrocentesis at the lighter end, open joint procedures at the other.

ChondroFiller injection offers a different path. Delivered as an outpatient procedure under ultrasound or augmented-reality image guidance, it places a regenerative collagen scaffold directly into the TMJ joint space — no operating theatre, no incisions, no general anaesthetic. The mechanism is acellular matrix-induced chondrogenesis: once injected, the collagen solution gels in situ and provides a chemotactic matrix that recruits the patient's own progenitor cells, which then begin building new cartilage as the scaffold is gradually resorbed.

This article covers how that process works within the specific anatomy of the TMJ, why image guidance is essential for safe and accurate delivery in this joint, what the current evidence shows, and which patients are most likely to be suitable candidates.

Why TMJ cartilage is different from knee cartilage

The TMJ is anatomically unlike any other joint routinely treated with cartilage scaffolds. Its articular surfaces are lined with fibrocartilage — a denser, more fibrous tissue than the hyaline cartilage found in the knee — and any regenerative scaffold placed here must integrate with that distinct substrate rather than the tissue type for which most cartilage repair protocols were originally designed.

Surrounding anatomy adds further precision demands. The mandibular condyle sits in close proximity to major blood vessels and branches of the trigeminal nerve; there is no margin for imprecise needle placement. Ultrasound-guided injection to the TMJ has been shown to improve delivery accuracy and reduce the risk of damage to those adjacent structures — a consideration that does not arise to the same degree in larger peripheral joints.

The joint's internal volume is also considerably smaller than the knee, which means injection volumes and delivery protocols developed for larger joints cannot be transferred directly without adaptation.

The typical patient profile is a further distinguishing feature. Imaging-confirmed TMJ degenerative joint disease tends to present at a mean age of approximately 30, and around 87% of cases occur in women — a notably younger and predominantly female population compared with typical knee or hip osteoarthritis cohorts. That profile shapes how candidacy is assessed rather than limiting who can be considered.

Finally, the local inflammatory environment in TMJ osteoarthritis — elevated levels of matrix-degrading enzymes including MMP-1, MMP-3, and ADAMTS-4, alongside mediators such as IL-6 — can affect scaffold integration if left unaddressed. Concurrent anti-inflammatory management is therefore a practical planning consideration, not an afterthought.

How ChondroFiller injection works as a regenerative scaffold

Once ChondroFiller's Type I collagen solution enters the joint space, it undergoes rapid in-situ polymerisation — within minutes, the fluid transitions into a stable viscoelastic gel that bonds to the adjacent fibrocartilage surfaces. The gel then acts as a chemotactic matrix, releasing signals that draw the patient's own stem and progenitor cells from the surrounding synovium and subchondral tissue into the scaffold. Those cells differentiate into chondrocytes and begin producing new matrix. As repair proceeds, the scaffold is gradually resorbed and replaced by endogenous fibrocartilage — the tissue type the TMJ relies on. This sequence is what the term acellular matrix-induced chondrogenesis describes: no donor cells are injected, and no cartilage cells are harvested; the scaffold supports the body's own repair processes.

There is specific laboratory evidence supporting the availability of a local progenitor pool in the TMJ. A 2024 in vitro study of TMJ condyle cells found that scaffold material — not cell type — was the primary driver of chondrogenic differentiation. Notably, superficial fibroblastic layer cells showed equivalent chondrogenic potential to deeper cartilage-layer cells, suggesting that a regenerative scaffold placed at the TMJ surface would encounter a responsive tissue environment.

ChondroFiller is a CE-marked Class III medical device composed of murine-derived Type I collagen. Clinical studies in the knee and wrist have used a 2.3 mL injection volume; the TMJ's considerably more compact anatomy means delivery parameters will likely need adaptation for this joint.

Where damage is more advanced, that delivery picture extends further. A combination protocol can pair ChondroFiller — the regenerative scaffold — with Arthrosamid, a polyacrylamide hydrogel used to provide synovial cushioning. The two address different mechanical problems in the joint and work through entirely distinct mechanisms; they are not interchangeable and should not be grouped as a single therapy.

Why image guidance is essential for TMJ scaffold placement

Placing a collagen scaffold accurately within the compact space of the TMJ requires real-time imaging — not as a precaution, but as a procedural necessity given the neurovascular structures immediately adjacent to the condyle.

A 2024 review of ultrasound-guided TMJ injection confirmed that ultrasound improves both placement accuracy and therapeutic efficacy compared with landmark-based techniques, whilst simultaneously allowing the clinician to assess capsulitis, internal derangement, and degenerative joint changes in the same session. That dual role — guidance and diagnostic clarity — is particularly relevant when delivering a scaffold that must reach the target site precisely in order to polymerise and bond correctly.

More recent evidence comes from a 2025 pilot RCT that tested augmented-reality guidance using a visual-inertial odometry (VIO) algorithm calibrated to each patient's segmented condylar anatomy. The ten patients in the AR-guided group achieved significant pain reduction on VAS scoring and improved lateral mandibular movement, establishing proof of concept that technology-assisted precision delivery is both feasible and clinically meaningful. It is worth noting that this trial examined pericapsular rather than intra-articular injection; the two target sites are not identical, and both bodies of evidence should be read as complementary rather than interchangeable.

What both approaches share is the same underlying principle: the TMJ does not accommodate imprecision. That principle is what makes image guidance a standard element of the procedure rather than an optional upgrade. At the London Cartilage Clinic on Harley Street, ChondroFiller injection into the TMJ is performed under ultrasound guidance as standard — a protocol delivered by Professor Paul Y. F. Lee, reflecting the degree of technique sensitivity that this anatomy demands.

What the evidence shows — and what it does not yet confirm

Existing clinical data from ChondroFiller in other joints provides a reliable performance benchmark. In knee applications, IKDC scores have improved by approximately 30 points over 12 months; in the wrist, post-treatment MRI has confirmed structural changes — reduced bone marrow oedema, diminished periarticular effusion, and measurable joint-space widening. These are structural outcomes, not symptom proxies alone.

For the TMJ specifically, animal research supports the principle of scaffold-driven repair in this joint. A 2020 goat study using a bilayered hydrophilic/hydrophobic scaffold at condylar defect sites produced hierarchical neo-cartilage — ordered fibrocartilage over hyaline cartilage, matching natural condylar anatomy — within two months of implantation. The scaffold design and delivery method differed from ChondroFiller injection, so the finding does not transfer directly; it does, however, confirm that the TMJ fibrocartilage environment can respond to scaffold-mediated regeneration.

A 2019 RCT of intra-articular TMJ injection adds useful context. Bone marrow nucleated cell concentrate outperformed hyaluronic acid on pain relief, chewing efficiency, and mouth opening at both 6 and 12 months — yet neither group produced MRI evidence of cartilage regeneration. Functional benefit without structural change is precisely the gap a scaffold-based approach is designed to address.

What the current literature does not yet include is a published clinical trial of ChondroFiller injection specifically in the human TMJ. The case for TMJ application rests on mechanism extrapolation from other joints and the analogous scaffold science described above — a credible biological foundation, but one that has not yet been tested in a dedicated TMJ trial. Patients considering this pathway should hold both in view: the biological rationale is well-grounded, and TMJ-specific trial data remains an acknowledged evidence horizon.

Who is likely to benefit and how to take the next step

The picture that emerges from the evidence is one of a biologically credible pathway delivered with an appropriate level of precision — and practically, that translates into a question of whether a patient's imaging and disease stage sit within the window where a scaffold can bond to viable fibrocartilage and recruit from the progenitor cells around it. That window most clearly fits early-to-moderate degenerative change: jaw pain that disrupts eating or speech, clicking with restricted mouth opening, and MRI-confirmed cartilage loss that has not yet reached end-stage. Younger adults — the demographic that TMJ degenerative joint disease disproportionately affects — have particular reason to consider this before progression narrows the available options, precisely because joint replacement is a poor horizon at that age.

For more advanced presentation, the clinical team may consider whether ChondroFiller injection is more appropriately used alongside a synovial cushioning agent. Whether that combination is warranted, and how it is structured, depends on imaging and examination rather than a fixed protocol.

The procedure is carried out as an outpatient injection under ultrasound guidance at the London Cartilage Clinic on Harley Street — no general anaesthetic or overnight stay is required. An initial assessment reviews current imaging, establishes the stage of disease, and determines whether ChondroFiller injection alone or in combination is appropriate for the individual.

Assessments can be booked at londoncartilage.com.

1. [1] Ultrasound Image-guided Injection to Temporomandibular Joint. (2024). https://doi.org/10.22974/jkda.2024.62.7.003 https://doi.org/10.22974/jkda.2024.62.7.003
2. [2] TMJ Pericapsular Guided Injection with Visual-Inertial Odometry (Augmented/Mixed Reality): a Novel Pilot Clinical Approach for Joint Osteoarthrosis Drug Delivery. (2025). https://doi.org/10.1016/j.jdent.2025.105659 https://doi.org/10.1016/j.jdent.2025.105659
3. [3] Temporomandibular joint. https://en.wikipedia.org/?curid=203139 https://en.wikipedia.org/?curid=203139
4. [4] Chondrogenic potential of superficial versus cartilage layer cells of the TMJ condyle in photopolymerizable gelatin-based hydrogels. (2024). https://doi.org/10.1177/09544119241267021 https://doi.org/10.1177/09544119241267021
5. [5] TMJ degenerative joint disease: relationships between CBCT findings, clinical symptoms, and signs. (2023). https://doi.org/10.1080/00016357.2023.2215317 https://doi.org/10.1080/00016357.2023.2215317
6. [6] Bone marrow nucleated cell concentrate autograft in temporomandibular joint degenerative disorders: 1-year results of a randomized clinical trial. (2019). https://doi.org/10.1016/J.JCMS.2018.11.025 https://doi.org/10.1016/J.JCMS.2018.11.025
7. [7] A Bilayered Scaffold with Segregated Hydrophilicity-Hydrophobicity Enables Reconstruction of Goat Hierarchical Temporomandibular Joint Condyle Cartilage. (2020). https://doi.org/10.1016/j.actbio.2020.11.031 https://doi.org/10.1016/j.actbio.2020.11.031
8. [8] Nrf2/ARE is a key pathway for curcumin-mediated protection of TMJ chondrocytes from oxidative stress and inflammation. (2020). https://doi.org/10.1007/s12192-020-01079-z https://doi.org/10.1007/s12192-020-01079-z